Ann: Leadership Changes and Strategic Review, page-15

3D I listened to the conference call the other day. When it got to questions De Souza was like a fish out of water. Instos wanted him to be candid about the raising being part of a loan requirement being forced upon them - he wasn't. They also raised that their previous cash raise was also done at a low price - indicating inability to plan.

Another insto called him out on his numbers not adding up between (in relation to their different cash burn rates).

He also didn't seem to understand that dropping support of 210 would mean the company would effectively be going from a clinical biotech to a pre-clinical biotech. (the mind boggles)

I'd be very interested to learn what was asked at the AGM today. 

I'd also be interested to know if the board has been asked whether they are going to take up their entitlements.